GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

"NICE approves GSK’s belantamab mafodotin for blood cancer" was originally created and published by Pharmaceutical Technology ...

England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

The US Food and Drug Administration (FDA) announced a forthcoming public advisory committee meeting (AdCom) of the Oncologic Drugs Advisory Committee to review GSK’s marketing application for Blenrep ...

Blenrep, which is predicted by analysts to produce revenues of around $1.5bn in 2026, is an antibody-drug conjugate that works by targeting B-cell maturation antigen (BCMA), a protein commonly ...

A “TROJAN HORSE” therapy that sneaks toxic drugs inside and kills cancer cells is being rolled out on the NHS in England in a ...

Consequently, Blenrep monotherapy as a treatment for relapsed or refractory multiple myeloma was also withdrawn from the EU market. Now that the Blenrep combo has already been approved in Japan ...

Terminal patients could get years more with their loved ones as the NHS offers Blenrep, which can put some blood cancer patients in remission ...

Blood cancer patients in England are set to be among the first in the world to access a pioneering "Trojan horse" treatment, ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a positive opinion for Blenrep (belantamab mafodotin) for the treatment of relapsed or ...

Blenrep combo nearly tripled PFS to 36.6 months vs 13.4 months in DREAMM-7. Blenrep cut risk of death by 42% vs comparator in DREAMM-7 at 39.4-month median follow-up. Feel unsure about the market ...